Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $26 price target on Exelixis after its management’s presentation at the annual Piper Jaffray Healthcare Conference. The analyst notes that its CABOMETYX is the tyrosine kinase inhibitor choice in the 2nd and 3rd line kidney cancer. Tenthoff adds that although immuno-oncology drugs are starting to dominate Renal Cell Carcinoma, CABOMETYX is still “competitively positioned with a better potency and safety profile”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.